Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

PURPOSE: To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. METHODS: Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the I...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Phillips, Kelly-Anne, Milne, Roger L., Rookus, Matti A., Daly, Mary B., Antoniou, Antonis C., Peock, Susan, Frost, Debra, Easton, Douglas F., Ellis, Steve, Friedlander, Michael L., Buys, Saundra S., Andrieu, Nadine, Noguès, Catherine, Stoppa-Lyonnet, Dominique, Bonadona, Valérie, Pujol, Pascal, McLachlan, Sue Anne, John, Esther M., Hooning, Maartje J., Seynaeve, Caroline, Tollenaar, Rob A.E.M., Goldgar, David E., Beth Terry, Mary, Caldes, Trinidad, Weideman, Prue C., Andrulis, Irene L., Singer, Christian F., Birch, Kate, Simard, Jacques, Southey, Melissa C., Olsson, Håkan L., Jakubowska, Anna, Olah, Edith, Gerdes, Anne-Marie, Foretova, Lenka, Hopper, John L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2013
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3753701/
https://ncbi.nlm.nih.gov/pubmed/23918944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.8313
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak